News

GlyTR in Orange County Business Journal

Irvine Biotech Firm Pursues Cancer Cure By Yuika Yoshida October 27, 2025 The University of California, Irvine has licensed a new cancer-fighting immunotherapy to biotech firm GlyTR Therapeutics Inc. for commercialization, paving the way for what researchers call a potential “holy grail” treatment of multiple cancers. The new immunotherapy discovery is a breakthrough, as there is currently no single pan-cancer therapy, according to UCI. It has the potential to target and destroy several major cancer types, including breast, colon, lung and prostate, university officials said. “It’s… Read More »GlyTR in Orange County Business Journal

GlyTR Therapeutics announces landmark study in Cell on their ‘Velcro-like’ Pan-Cancer Immunotherapy Platform

IRVINE, Calif., Oct. 9, 2025 /PRNewswire/ — GlyTR Therapeutics, a biotech company pioneering development of glycan-targeting cancer immunotherapies, announced the publication of its foundational technology in the journal, Cell. “With the publication in Cell, GlyTR is entering the global spotlight,” said Bob Genthert, Co-Founder and Interim CEO. “This is a critical milestone as we advance toward clinical trials and expand partnerships with investors, academic collaborators, and pharmaceutical companies.” The study details Glycan-Dependent T cell Recruiter (GlyTR1 & GlyTR2) therapeutics that have pan-cancer activity by targeting tumor-associated carbohydrate antigens (TACAs). The TACA’s targeted by GlyTR are… Read More »GlyTR Therapeutics announces landmark study in Cell on their ‘Velcro-like’ Pan-Cancer Immunotherapy Platform

GlyTR Therapeutics ‘Cancer Moonshot’ Technology Receives Second Grant from the National Cancer Institute

IRVINE, Calif.–(BUSINESS WIRE)–GlyTR Therapeutics, Inc. is pleased to announce it has been awarded an approximately $300,000 grant from The National Cancer Institute (NCI), National Institute of Health (NIH) thru the Small Business Technology Transfer Program. This grant award comes on the heels of a $3.4 million grant on its Glycan dependent T cell Recruiter (GlyTR – pronounced ‘glitter’) technology received in September from the Beau Biden Cancer Moonshot initiative at NCI. The new funding will support the company’s development of highly novel cancer immunotherapies that trigger the… Read More »GlyTR Therapeutics ‘Cancer Moonshot’ Technology Receives Second Grant from the National Cancer Institute

UCI awarded $3.4M NIH “Cancer Moonshot” grant to study potential breakthrough in cancer immunotherapy

Novel GlyTR technology may markedly broaden the types of cancers sensitive to immunotherapy Irvine, Calif. – September 27, 2018 – UCI School of Medicine researchers have been awarded a $3.4 million grant by the National Cancer Institute (NCI) as part of the Beau Biden Cancer Moonshot initiative. The funding will support efforts to provide proof of principal data for an entirely new class of cancer killing immunotherapeutics with the potential to treat highly diverse types of cancer, from leukemia to breast cancer. Principal investigator, Michael… Read More »UCI awarded $3.4M NIH “Cancer Moonshot” grant to study potential breakthrough in cancer immunotherapy